• 1
    Raaphorst GP, Szekely JG. Thermal enhancement of cellular radiation damage: a review of complementary and synergistic effects. Scanning Microsc. 1988; 2: 513-535.
  • 2
    Dewhirst MW, Vujaskovic Z, Jones E, Thrall D. Re-setting the biologic rationale for thermal therapy. Int J Hyperthermia. 2005; 21: 779-790.
  • 3
    Franceschi C. Cell proliferation, cell death and aging. Aging (Milano). 1989; 1: 3-15.
  • 4
    Fuller KJ, Issels RD, Slosman DO, Guillet JG, Soussi T, Polla BS. Cancer and the heat shock response. Eur J Cancer. 1994; 30A: 1884-1891.
  • 5
    Arya R, Mallik M, Lakhotia SC. Heat shock genes—integrating cell survival and death. J Biosci. 2007; 32: 595-610.
  • 6
    Falk MH, Issels RD. Hyperthermia in oncology. Int J Hyperthermia. 2001; 17: 1-18.
  • 7
    Fosmire H, Hynynen K, Drach GW, Stea B, Swift P, Cassady JR. Feasibility and toxicity of transrectal ultrasound hyperthermia in the treatment of locally advanced adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1993; 26: 253-259.
  • 8
    Algan O, Fosmire H, Hynynen K, et al. External beam radiotherapy and hyperthermia in the treatment of patients with locally advanced prostate carcinoma. Cancer. 2000; 89: 399-403.
  • 9
    Hurwitz MD, Kaplan ID, Hansen JL, et al. Hyperthermia combined with radiation in treatment of locally advanced prostate cancer is associated with a favourable toxicity profile. Int J Hyperthermia. 2005; 21: 649-656.
  • 10
    Pilepich MV, Krall JM, al-Sarraf M, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology. 1995; 45: 616-623.
  • 11
    Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol. 1997; 15: 1013-1021.
  • 12
    Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997; 337: 295-300.
  • 13
    Van Vulpen M, De Leeuw JR, Van Gellekom MP, et al. A prospective quality of life study in patients with locally advanced prostate cancer, treated with radiotherapy with or without regional or interstitial hyperthermia. Int J Hyperthermia. 2003; 19: 402-413.
  • 14
    Johannsen M, Gneveckow U, Taymoorian K, et al. Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: results of a prospective phase I trial. Int J Hyperthermia. 2007; 23: 315-323.
  • 15
    Anscher MS, Samulski TV, Dodge R, Prosnitz LR, Dewhirst MW. Combined external beam irradiation and external regional hyperthermia for locally advanced adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1997; 37: 1059-1065.
  • 16
    Deger S, Taymoorian K, Boehmer D, et al. Thermoradiotherapy using interstitial self-regulating thermoseeds: an intermediate analysis of a phase II trial. Eur Urol. 2004; 45: 574-580.
  • 17
    Tilly W, Gellermann J, Graf R, et al. Regional hyperthermia in conjunction with definitive radiotherapy against recurrent or locally advanced prostate cancer T3 pN0 M0. Strahlenther Onkol. 2005; 181: 35-41.
  • 18
    Maluta S, Dall'Oglio S, Romano M, et al. Conformal radiotherapy plus local hyperthermia in patients affected by locally advanced high risk prostate cancer: preliminary results of a prospective phase II study. Int J Hyperthermia. 2007; 23: 451-456.
  • 19
    Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003; 21: 3972-3978.
  • 20
    D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. Six-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004; 292: 821-827.
  • 21
    Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005; 6: 841-850.
  • 22
    Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 70: 67-74.
  • 23
    Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Uzzo RG, Hanks GE. Prostate cancer radiotherapy dose response: an update of the Fox Chase experience. J Urol. 2004; 171: 1132-1136.